Thursday, April 7, 2022 11:00 am-12:00 pm Eastern
This interactive live webinar is part 9 of the Emerging and Evolving Biomarkers Series.
Description:B-cells and T-cells have the unique characteristic of undergoing DNA rearrangement of the immunoglobulin or T-cell receptor gene loci, respectively, in order to differentiate into mature lymphoid cells. The genetic mark of these rearrangements separates these cells from all other cell types in the body, which maintain an intact germline configuration of these genes. The identification of specific rearrangements, initially by Southern blot and later by PCR, has enabled the use of B-cell and T-cell clonality as a diagnostic test for lymphoid malignancies. The development and application of next-generation sequencing to these genes has opened new avenues for minimal residual disease monitoring, immune repertoire profiling and precision immuno-oncology, as well as opportunities for non-invasive cancer diagnostics. The history and discovery of these genes, sequencing techniques used to identify these rearrangements, and the clinical applications of next-generation sequencing of these genes will be reviewed.
Learning Objectives:
- Identify genes targeted for clonality assessment in lymphoid malignancies.
- Compare sequencing techniques used for clonality assessment.
- Describe diseases for which immunoglobulin sequencing can guide patient management.
- Describe diseases for which T-cell receptor sequencing can guide patient management.
 |
 |
|---|---|
|
Speaker:
Rena Xian, MD |
Moderator:
Lauren Ritterhouse, MD, PhD |
Duration: 1 Hour
This program has been supported through educational grant funding provided by Amgen and Loxo Oncology at Lilly (for further information concerning Lilly grant funding visit www.lillygrantoffice.com.) Supporting companies had no control over its content. No personally-identifiable information regarding you is provided to any grant supporters.
- Click the "Register Now" Button
- Log in using your AMP credentials. If you do not have an AMP account, Create a FREE account.
- Complete the "Demographic questionnaire for Emerging and Evolving Biomarkers Series" before the webinar date. You will only need to do this once for the entire series.
Continuing Education Credit Information
CME credit: 1.0CMLE credit: 1.0
Last day to claim credit: May 7, 2022
Accreditation Statements
AMA PRA Category 1 Credit(s)™
This
activity has been planned and implemented in accordance with the
Essential Areas and policies of the Accreditation Council for Continuing
Medical Education through the joint providership of American Society
for Clinical Pathology (ASCP) and Association for Molecular Pathology
(AMP). The American Society for Clinical Pathology (ASCP) is accredited
by the ACCME to provide continuing medical education for physicians.
The ASCP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
CMLE
This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology for 1.0 hours
of CMLE credit. ASCP CMLE credit hours are acceptable for the ASCP
Board of Certification (BOC) Certification Maintenance Program
(CMP). CMLE credit hours meet the continuing education requirements for
the ASCP Board of Certification Credential Maintenance Program (CMP) and
state relicensure requirements for laboratory personnel. Participants
should claim only the credit commensurate with the extent of their
participation in the activity.
Note: Join the AMP Family for discounted access to the most current educational resources!
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentation.
